RXi Pharmaceuticals Announces Positive Results with RXI?109 in the Eyes of Cynomolgus Monkeys as Part of a Dose Range Finding Study
PR Newswire - Fri May 02, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection, of RXI--109 in the eyes of cynomolgus monkeys, as part of a dose-range finding study to build the Company's ophthalmology franchise.
RXi Pharmaceuticals begins phase 2a study of RXI-109 in keloid patient
M2 - Wed Apr 30, 4:02AM CDT
Biotechnology company RXi Pharmaceuticals (NasdaqCM:RXII) revealed on Tuesday that the first patient has been admitted in its second Phase 2a study of RXI-109 for the prevention of keloid recurrence.
RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
PR Newswire - Tue Apr 29, 12:03PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the first patient has enrolled in their Phase 2a study (RXI-109-1401) with RXI-109 for the prevention of keloid recurrence. RXI-109 is an sd-rxRNA® compound that targets connective tissue growth factor (CTGF) and is being developed for the treatment of abnormal dermal scars, such as hypertrophic scars and keloids, in conjunction with scar or keloid revision surgery. Phase 1 studies have shown that RXI-109 is safe and well tolerated. In addition, RXI-109 was shown to reduce CTGF mRNA in line with its mechanism of action by up to 50% in healthy volunteers with the doses tested. Excessive production of CTGF is considered a major cause of abnormal scarring, such as hypertrophic scars and keloids.
RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting
PR Newswire - Mon Apr 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies today announced that the Company will present at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting.
RXi Pharmaceuticals Enters into Financing Facility with Lincoln Park Capital
PR Newswire - Tue Apr 22, 2:29PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that it has entered into a purchase agreement (the "Purchase Agreement"
RXi Pharmaceuticals Reports Full Year 2013 Financial Results
PR Newswire - Fri Mar 28, 3:45PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
RXi Pharmaceuticals Announces Upcoming Presentations
PR Newswire - Fri Mar 14, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced upcoming presentations at the 6th Ocular Diseases and Drug Development Conference, the 72nd Annual Meeting of the American Academy of Dermatology ("AAD"
RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
PR Newswire - Wed Mar 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the U.S. Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI--109, for the treatment of fibrotic disorders. U.S. Patent Number 8,664,189, will expire in 2029. The Notice of Allowance was released on January 14, 2014 for this patent.
RXi Pharmaceuticals to Present at the 26th Annual ROTH Conference
PR Newswire - Tue Mar 04, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 4:30pm PST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.
RXi Pharmaceuticals (RXII) Jumps: Stock Adds 28.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
RXi Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 29% on the day.
RXi Pharmaceuticals to Present at the 24th Annual Wall Street Analyst Forum
PR Newswire - Mon Feb 24, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 24th Annual Wall Street Analyst Forum on Monday, March 3, 2014 at 12:50pm EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.
OTC Markets Group Congratulates RXI Pharmaceuticals on NASDAQ Listing
PR Newswire - Tue Feb 11, 9:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM) congratulates RXI Pharmaceuticals Corp. (NASDAQ: RXII) on its approval to list on the NASDAQ Capital Market. RXI is moving to NASDAQ from OTCQX®, the best marketplace for qualified companies.
RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ"
RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 03, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30am EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics
ACCESSWIRE - Fri Jan 24, 9:06AM CST
RNA interference ("RNAi"
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
PR Newswire - Tue Jan 14, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.
NIH Data Sharing Projects Could Accelerate RNAi Field
ACCESSWIRE - Wed Jan 08, 10:16AM CST
The RNA industry could receive a significant boost this year after the National Institute of Health ("NIH"
RXi Pharmaceuticals to Present at the Biotech Showcase(TM) 2014
PR Newswire - Mon Jan 06, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the Biotech Showcase(TM) 2014 conference on Tuesday, January 14, 2014 at 9:30AM PST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd--rxRNA® technology platform.
Surgical Scar Market Is Ripe for Innovation
ACCESSWIRE - Wed Dec 18, 10:15AM CST
Scarring is an inevitable consequence of dermal wounds - such as those incurred during routine surgeries - that has a profound impact on physical appearance and psychological well-being. Despite high demand for therapies that prevent or reduce dermal scarring, there are few treatment options approved by the U.S. Food & Drug Administration ("FDA"
RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
PR Newswire - Wed Dec 04, 7:05AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced additional results from their second placebo-controlled Phase 1 study with RXI--109, an sd-rxRNA® compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.